- Home
- »
- Healthcare IT
- »
-
Manufacturing Execution System in Life Sciences Market Report, 2033GVR Report cover
Manufacturing Execution System In Life Sciences Market (2026 - 2033)
Size, Share & Trends Analysis Report By Solution Type, By Deployment (On-Premise, Cloud/Web-Based, Hybrid), By End-User (Pharmaceutical and Biotechnology Companies, Medical Device Companies), By Region, And Segment Forecasts
Market Size, 2025
$3.3BMarket Estimate, 2026
$3.7BMarket Forecast, 2033
$8.7BCAGR, 2026–2033
13.2%Manufacturing Execution System in Life Sciences Market Summary
The global manufacturing execution system in life sciences market size was valued at USD 3.3 billion in 2025 and is projected to grow from USD 3.7 billion in 2026 to USD 8.7 billion by 2033, at a CAGR of 13.2% from 2026 to 2033. The market in North America dominated with a revenue share of 31.6% in 2025. The increasing regulatory compliance, demand for real-time data and analytics, growing biopharmaceutical sector, technological advances, and globalization of the life sciences industry are some of the factors driving the demand for manufacturing execution systems in life sciences industry.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,
Download Free Sample Report Key Market Trends & Insights
- By solution type: Software segment held the largest market share of 59.3% in 2025.
- By deployment: On-premise segment held the largest market share of 50.0% in 2025.
- By end-user: Pharmaceutical and biotechnology companies segment held the largest market share of 48.2% in 2025.
Regional Highlights
- Largest regional market: North America (31.6% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The U.S. held the largest market share in 2025
Market Size & Forecast
- Market size in 2025: USD 3.3 Billion
- Estimated market size in 2026: USD 3.7 Billion
- Projected market size by 2033: USD 8.7 Billion
- CAGR (2026-2033): 13.2%
Prism AI by Grand View Research Free to tryAsk a question about the manufacturing execution system in life sciences marketTry asking✓Every figure cited from GVR research Prefer the report? Download free sample →
The increasing regulatory compliance, demand for real-time data and analytics, growing biopharmaceutical sector, technological advances, and globalization of the life sciences industry are some of the factors driving the demand for manufacturing execution systems in life sciences industry. The pharmaceutical industry is increasingly adopting digitization, driving the demand for Pharma 4.0 and manufacturing execution systems (MES) in the life sciences market. Pharma 4.0 enhances connectivity, productivity, compliance, and information management to address challenges effectively.
To learn more about this report, Download Free Sample Report Developed by the International Society for Pharmaceutical Engineering (ISPE), this model revolutionizes manufacturing processes with more human-centric workflows, leveraging digitalization for faster therapeutic innovations and improved production processes for patient benefit. Moreover, the growing complexity of pharmaceutical and biotechnology manufacturing, along with the need for precise data management, has propelled MES demand in life sciences sector. These systems offer centralized platforms for data integration, process optimization, and quality assurance, thereby boosting overall productivity. In addition, the rise of personalized medicine and demand for innovative therapies have increased production intricacies, driving MES adoption to manage manufacturing complexities in the life sciences sector.
As the industry evolves and undergoes digital transformation, MES is set to play a crucial role in facilitating efficient, agile, and compliant manufacturing operations, driving sustained market growth. In August 2020, a survey sponsored by Appian highlighted the adoption of automation in the global life sciences and pharmaceutical industry. According to the survey, most respondents engaged in digital modernization efforts aimed at enhancing process and operational efficiency. However, automation is currently utilized in only 40% of respondents' organizations, with 75% anticipating the adoption of automation technologies in the future.
Market Dynamics
The rapid digital transformation of pharmaceutical, biotechnology, and medical device manufacturing is the primary driver of the manufacturing execution system (MES) in life sciences market. As manufacturers strive to improve production efficiency, ensure regulatory compliance, and accelerate product commercialization, MES solutions have become a critical component of modern manufacturing operations. These platforms bridge the gap between enterprise-level planning systems and shop-floor production by enabling real-time monitoring, process automation, electronic batch recording, and end-to-end manufacturing visibility.
Moreover, the increasing emphasis on Good Manufacturing Practices (GMP) and stringent regulatory requirements imposed by agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global health authorities. Life sciences manufacturers are required to maintain complete production traceability, data integrity, and electronic documentation while complying with regulations such as 21 CFR Part 11, Annex 11, and EU GMP guidelines. MES platforms automate batch documentation, enforce standardized operating procedures, maintain secure audit trails, and reduce manual recordkeeping, enabling manufacturers to achieve compliance while minimizing the risk of regulatory observations and product recalls.
High implementation cost and complexity associated with manufacturing execution system (MES) deployment remain significant restraints for the manufacturing execution system in life sciences market. Implementing an MES requires substantial upfront investment in software licensing or subscriptions, system integration, validation, infrastructure upgrades, cybersecurity, and employee training. For pharmaceutical, biotechnology, and medical device manufacturers operating legacy production environments, integrating MES with existing Enterprise Resource Planning (ERP), Laboratory Information Management Systems (LIMS), Quality Management Systems (QMS), Supervisory Control and Data Acquisition (SCADA), and automation equipment is often technically challenging and resource-intensive.
The growing adoption of artificial intelligence (AI), cloud computing, and smart manufacturing technologies presents a significant opportunity for the manufacturing execution system (MES) in life sciences market. Pharmaceutical and biotechnology manufacturers are increasingly moving beyond traditional manufacturing execution toward intelligent, data-driven production environments that enable predictive decision-making, autonomous process optimization, and real-time operational visibility. AI-powered MES platforms can analyze production data to predict equipment failures, optimize production scheduling, detect process deviations, improve batch quality, and recommend corrective actions before quality issues occur, reducing manufacturing downtime and operational costs.
Market Concentration & Characteristics
MES in life sciences market exhibits a high degree of innovation due to the integration of MES with Pharma 4.0, AI, and IoT, accelerating digital transformation in the industry
To learn more about this report, Download Free Sample Report The MES market in life sciences sees a moderate to high level of merger and acquisition (M&A) activity among major players. Key players undertake strategic initiatives, such as geographical expansion, innovations, collaborations, and partnerships to strengthen their market presence. For instance, in January 2022, POMS Corporation launched new MES Dashboards and Batch Records for drug manufacturers in the pharmaceutical, biotech, and cell and gene industries. This launch is expected to offer significant benefits to manufacturers in these sectors
MES in life sciences market faces increasing regulatory scrutiny due to the growing complexity of regulations in pharmaceutical and medical device sectors. Regulations, such as Good Manufacturing Practice (GMP) and Good Automated Manufacturing Practice (GAMP), impose stringent requirements on system validation. MES solutions must undergo validation to consistently meet predefined specifications and comply with regulatory standards
The threat of substitute products is expected to be low to moderate in this market. MES uniquely controls, monitors, and digitally documents processes in real-time throughout the production cycle, making it a unique product in the market
End-users in the MES in life sciences market include pharmaceutical and biotechnology companies, Medical Device Companies, and Others (CDMOs, CROs, etc.). These users are increasingly adopting MES solutions to track and control the drug product lifecycle. Notable companies like Terumo Corporation, Thermo Fisher Scientific Inc., Fagron, and Teknor Apex are among the users currently utilizing MES solutions
Analyst Perspective
The manufacturing execution system (MES) in life sciences market is entering a new phase of growth, driven by the convergence of digital manufacturing, regulatory compliance, and intelligent automation. While MES has traditionally focused on production execution and electronic batch records, next-generation platforms are evolving into integrated manufacturing intelligence solutions by incorporating artificial intelligence, cloud computing, Industrial IoT, and advanced analytics. Demand is expected to accelerate as pharmaceutical and biotechnology companies expand biologics, cell and gene therapy, and personalized medicine manufacturing. Vendors that offer scalable, AI-enabled, interoperable, and cloud-native MES platforms with strong GMP compliance capabilities will be best positioned to capture long-term market opportunities.
MES Implementation Case Studies
-
Repligen Corporation: Repligen, a life sciences company, implemented Emerson's Syncade Smart Operation Management Suite to enhance document control and revisions. This system significantly reduced production record issuance time from 4 hours to just one to two hours and decreased quality assurance time from approximately 16 hours to 4 to 6 hours per week. Syncade automated the review and approval process for controlled documents, ensuring adherence to schedule and garnering appreciation from Repligen's FDA-regulated customers
-
Tech Group: E Tech Group installed a $1.8 million process control system at Massachusetts Biologic Laboratories. The system, based on PLC and SCADA, utilizes Allen-Bradley ControlLogix 5550 processors with I/O, solenoid blocks, and scale indicators. PCS communicates 400 data points over Ethernet to various vendor-supplied equipment systems and includes a fault-tolerant SCADA/Historian server, a fault-tolerant manufacturing execution system (MES) server, and 11 portable client workstations
The PCS incorporates a Manufacturing Execution System (MES) that assists with material tracking, equipment management, barcode recognition and creation, and electronic work instructions (EWI) to execute process steps at the MBL facility. Operators use barcode scanners to validate and log raw materials, semi-finished goods, finished goods, and equipment produced or utilized in the MBL facility
The COVID-19 pandemic impacted the MES within the life sciences market. The necessity for quick adjustment to remote work, social distancing measures, and strict hygiene protocols presented operational hurdles for MES implementation and maintenance. However, the pandemic accelerated the uptake of digital technologies in manufacturing, resulting in increased interest in MES solutions providing real-time visibility, agility, and automation.
Solution Type Insights
Based on solution type, the software segment dominated the market with the largest revenue share of 59.3% in 2025. The growing emphasis on data integrity, traceability, and regulatory compliance in the life sciences sector propels the adoption of MES software, as these systems provide a comprehensive framework for real-time monitoring and documentation. Furthermore, rising demand for end-to-end visibility across the entire manufacturing life cycle, from research and development to production and distribution, encourages life sciences companies to invest in MES solutions that offer seamless data integration and analytics capabilities.
The services segment is expected to grow at the fastest CAGR from 2026 to 2033. With the increasing digitization of manufacturing processes, there is a growing emphasis on data security and cybersecurity. MES service providers offer expertise in implementing robust security measures, protecting sensitive data, and ensuring compliance with industry standards. Such factors are expected to drive segment growth over the coming years.
Deployment Insights
Based on deployment, the on-premise segment led the market with the largest revenue share of 50.0% in 2025. On-premise solutions offer greater control over data security and privacy, addressing concerns related to sensitive information and intellectual property. In addition, life science companies often deal with large volumes of complex data generated during the manufacturing process, including critical parameters for quality control and batch tracking. On-premise MES solutions supply the necessary computing power and storage capacity to manage such data-intensive processes efficiently.
Furthermore, the need for seamless integration with existing enterprise resource planning (ERP) systems, laboratory information management systems (LIMS), and other legacy applications is crucial in the life science sector, owing to this, the cloud/web-based deployment segment is expected to grow at a significant CAGR from 2026 to 2033.
End-user Insights
Based on end use, the pharmaceutical and biotechnology companies segment led the market with the largest revenue share of 48.2% in 2025. The pharmaceutical industry is highly competitive and complex. To maintain a competitive edge, companies must scale operations, enhance processes, minimize errors, reduce lead times, and prioritize quality and compliance. MES solutions enable companies to manage production lines with precision, ensuring competitiveness. Biotechnology companies also benefit from MES by effectively managing the complex processes involved in producing biologics and personalized medicines.
To learn more about this report, Download Free Sample Report The medical device companies segment is expected to grow at the fastest CAGR of 13.7% from 2026 to 2033. Medical device production presents distinct challenges that companies must navigate to maintain competitiveness. Achieving this requires a delicate balance between cost reduction and regulatory compliance, alongside consistent production of high-quality products. MES solutions play a crucial role in ensuring quality, automating processes, and enforcing control over the five M's of manufacturing: Man, Measure, Machine, Method, and Material.
Regional Insights
North America dominated the MES in life sciences market with the largest revenue share of 31.6% in 2025. This region, comprising major economies like the U.S. and Canada, is highly technologically advanced, driving the digitization of manufacturing processes in the pharmaceutical industry. Key players, such as Apprentice FS, Inc.; Atachi Systems; POMS Corporation; Emerson Electric Co; and Rockwell Automation, play a crucial role in simplifying healthcare manufacturing processes, further bolstering the market growth in North America.
To learn more about this report, Download Free Sample Report U.S. MES in Life Sciences Market Trends
The MES in life sciences market in the U.S. held the largest share in the North America region in 2025. The manufacturing execution system in life sciences market in the U.S. is expected to grow significantly over the forecast period owing to the presence of key players and extensive adoption of software solutions in life science manufacturing. Moreover, the adoption of integrated laboratory automation solutions presents additional growth opportunities for MES providers. For example, Automata announced its intention to expand its services in the U.S. in February 2023.
Europe MES in Life Sciences Market Trends
Europe is the second-largest regional market witnessing increased adoption of advanced digital technologies and strategic partnerships facilitating MES implementation. Siemens' collaboration with BioNTech SE in June 2021 in converting a facility into a COVID-19 vaccine production site exemplifies this trend, accelerating project timelines significantly. Similarly, in December 2018, Körber AG's partnership with SPC Consultants aims to expand MES services in France, Belgium, and Switzerland, contributing to market growth.
MES in life sciences market in the UK benefits from increased healthcare spending and the integration of advanced technology solutions, such as cloud technologies and automated production processes.
Asia Pacific MES in Life Sciences Market Trends
The MES in life sciences market in Asia Pacific is expected to register the fastest CAGR of 15.4% during the forecast period, driven by the increasing number of pharmaceutical companies and presence of key market players. Asia Pacific shows promising growth prospects, driven by the increasing number of pharmaceutical companies and presence of key market players. Asian pharma manufacturers face challenges in maintaining product quality and compliance with legal requirements, leading to increased adoption of MES solutions to digitize production processes and enhance efficiency.
China MES in life sciences market is expected to grow at a significant CAGR from 2026 to 2033. This can be attributed to the increasing demand for quality drugs and the need to increase pharmaceutical production in the country owing to the growing population.
MES in life sciences market in India is primarily driven by various factors, such as the rising adoption of AI and cloud technologies in healthcare for improved patient outcomes. In addition, advancements in healthcare infrastructure and digitalization efforts to support the integration of software technologies to assist the production process is anticipated to impel market growth.
Key MES in Life Sciences Company Insights
Notable market players, such as Siemens AG, Emerson Electric Co., AVEVA Group Limited, Cognizant, Rockwell Automation, and MasterControl Solutions, Inc. are implementing various strategies, including collaborations, new product development, and partnerships, to bolster their market presence.
Key MES in Life Sciences Companies:
The following key companies have been profiled for this study on the MES in life sciences market.
-
Körber AG
-
ABB
-
MasterControl Solutions, Inc.
-
AVEVA Group Limited
-
Cognizant
-
Rockwell Automation
-
nagarro
-
Siemens AG
-
Emerson Electric Co.
-
iBase-t
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Established Players (Körber AG, Siemens AG, Rockwell Automation, Emerson Electric Co., Critical Manufacturing S.A.)
- Focus on end-to-end GMP-compliant MES platforms, continuous product innovation, cloud-enabled deployments, AI integration, strategic acquisitions, and long-term partnerships with pharmaceutical manufacturers.
- Strong domain expertise in life sciences manufacturing, extensive installed base, validated MES solutions, robust regulatory compliance capabilities, and global implementation support.
- High implementation cost, lengthy deployment cycles, and significant customization requirements for complex manufacturing environments.
Emerging Players (Nagarro SE, iBASEt, Inc., Cognizant)
- Target niche manufacturing segments with cloud-native, low-code, modular, and AI-enabled MES solutions designed for rapid deployment and flexible scalability.
- Faster implementation, lower total cost of ownership, cloud-first architecture, intuitive user experience, and agility in supporting modern manufacturing models.
- Smaller customer base, limited global service network, and lower brand recognition compared with established MES vendors.
Recent Developments
-
In January 2024, CGI Inc. joined forces with Körber AG to offer a comprehensive solution for enhancing the production processes of pharmaceutical and life sciences companies. By integrating CGI’s end-to-end Solution Types with Körber’s Werum PAS-X MES Suite, the partnership aims to facilitate improved accuracy, efficiency, and safety in the development of pharmaceutical products. Moreover, clients can leverage real-time data to make informative decisions and enhance their overall operations
-
In February 2023, AVEVA Group Limited, a prominent industrial software company, launched the new AVEVA Manufacturing Execution System. This new release aims to simplify the deployment of multi-site MES solutions and reduce their associated costs and complexities. With its latest version, AVEVA MES enables faster and more efficient implementation of best practices, which can lead to improved operational efficiency and sustainability
-
In September 2021, Honeywell International Inc. acquired Performix Inc., a private company that provides manufacturing execution system software for the pharmaceutical and biotech industries. This acquisition is part of Honeywell's strategy to become the world's leading provider of integrated software solutions for life sciences companies. The aim is to help clients achieve faster compliance, improved reliability, and better production throughput at the highest levels of quality
Manufacturing Execution System in Life Sciences Market Report Scope
Report Attribute
Details
Market size in 2025
USD 3.3 billion
Estimated market size in 2026
USD 3.7 billion
Projected market size by 2033
USD 8.7 billion
Growth rate
CAGR of 13.2% from 2026 to 2033
Historical data
2021 - 2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million/billion and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Solution type, deployment, end-user, region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Norway; Denmark; Sweden; Russia; Iceland; Finland; China; Japan; India; South Korea; Australia; Thailand; Singapore; Brazil; Argentina; Saudi Arabia; South Africa; UAE; Kuwait; Israel
Key companies profiled
Körber AG; Siemens AG; Rockwell Automation, Inc.; Emerson Electric Co.; AVEVA Group Limited; MasterControl Solutions Inc.; Critical Manufacturing S.A.; Honeywell International Inc.; SAP SE; ABB Ltd.; Cognizant Technology Solutions Corporation; Nagarro SE; iBASEt, Inc.; Dassault Systèmes SE
Customization scope
Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global MES in Life Sciences Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the MES in life sciences market report based on solution type, deployment, end-user, and region:
To learn more about this report, Download Free Sample Report -
Solution Type Outlook (Revenue, Million, 2021 - 2033)
-
Software
-
Services
-
-
Deployment Outlook (Revenue, Million, 2021 - 2033)
-
On-Premise
-
Cloud/Web-Based
-
Hybrid
-
-
End-user Outlook (Revenue, Million, 2021 - 2033)
-
Pharmaceutical and Biotechnology Companies
-
Medical Device Companies
-
Others (CDMOs, CROs, etc.)
-
-
Regional Outlook (Revenue, USD Million, 2021 - 2033)
-
North America
-
U.S
-
Canada
-
-
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Sweden
-
Denmark
-
Norway
-
-
Asia Pacific
-
China
-
Japan
-
India
-
South Korea
-
Australia
-
Thailand
-
-
Latin America
-
Brazil
-
Mexico
-
Argentina
-
-
Middle East and Africa (MEA)
-
Saudi Arabia
-
UAE
-
South Africa
-
Kuwait
-
-
Research Methodology
The manufacturing execution system in life sciences market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each manufacturing execution system in life sciences segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment - Solution Type
Revenue capture definition
Software
Revenue generated from the licensing, subscription (SaaS), and sale of MES software platforms used to manage, monitor, document, and optimize manufacturing operations in pharmaceutical, biotechnology, and medical device production. This includes core MES applications, electronic batch records (EBR), production scheduling, workflow management, quality management, equipment integration, genealogy & traceability, reporting, and analytics modules.
Services
Revenue generated from professional and managed services supporting MES implementation and lifecycle management, including consulting, system design, customization, validation (CSV), deployment, integration with ERP/LIMS/SCADA/QMS, user training, technical support, software maintenance, upgrades, cloud migration, and managed application services.
Segment - Deployment
Revenue capture definition
On-Premise
Revenue generated from MES solutions installed and operated within the customer's own manufacturing facilities or data centers. Includes perpetual software licenses, implementation, infrastructure-related deployment, maintenance contracts, and periodic upgrades.
Cloud/Web-Based
Revenue generated from cloud-hosted or SaaS-based MES solutions delivered through public, private, or multi-tenant cloud environments. Includes subscription fees, cloud hosting, platform management, software updates, cybersecurity services, and cloud support.
Hybrid
Revenue generated from MES deployments combining on-premise infrastructure with cloud-based applications or services, enabling organizations to retain critical manufacturing workloads on-site while leveraging cloud capabilities for analytics, reporting, remote monitoring, and scalability. Revenue includes hybrid software licensing, cloud subscriptions, integration, and support services.
Segment - End-user
Revenue capture definition
Pharmaceutical and
Biotechnology Companies
Revenue generated from MES software and related services deployed by pharmaceutical, biotechnology, vaccine, biologics, cell & gene therapy, and other life sciences manufacturers to manage GMP-compliant production, electronic batch records, process execution, quality control, and regulatory compliance across commercial and clinical manufacturing facilities.
Medical Device Companies
Revenue generated from MES deployments within medical device manufacturing facilities to support production execution, device traceability, quality management, electronic device history records (eDHR), process control, and compliance with regulatory standards such as FDA 21 CFR Part 820 and ISO 13485.
Others (CDMOs, CROs, etc.)
Revenue generated from MES solutions adopted by Contract Development and Manufacturing Organizations (CDMOs), Contract Research Organizations (CROs), contract packaging organizations, and other third-party manufacturing service providers. Revenue includes software and services used to manage multi-client manufacturing operations, production scheduling, batch traceability, regulatory compliance, technology transfer, and manufacturing execution for outsourced pharmaceutical and medical device production.
Estimation Model
Stage
Description
Top-Down
Commodity Flow Analysis: Market size was estimated by analyzing revenues generated by key in the MES in lifescience companies, supported by company annual reports, investor presentations, distributor insights, and premium databases. Revenue contributions from private companies were assessed using industry databases and validated through primary research to derive the overall market value.
Parent Market Model
Parent Market & Penetration-Based Analysis: The parent market approach for the MES in lifescience market begins with evaluating the overall life sciences tools and bioinformatics market, followed by isolating the share attributable to integrated omics technologies across genomics, proteomics, transcriptomics, and metabolomics platforms.
Segmentation
Country-Level Segment Share Modeling: Market shares for type, deployment mode, and end use segments were derived using country-specific adoption patterns, healthcare infrastructure, reimbursement scenarios, and product penetration rates. Weighted average calculations were applied to determine regional and global segment distributions.
Validation
Data Triangulation & Validation Model: Market estimates were validated through triangulation of secondary research, primary interviews, company-level revenue assessments, and demand-side adoption analysis to ensure consistency and accuracy across all market segments and geographies.
Forecasting
Forecasting & CAGR Modeling: Market forecasts were developed using historical market trends, technology adoption patterns, product innovation trends, healthcare expenditure, and regulatory developments. Regression-based analysis and trend modeling were applied to project future market growth and CAGR.
Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
AI-Enabled MES Adoption & Competitive Benchmarking
Conducted a cross-segment assessment comparing AI-enabled and conventional MES platforms across pharmaceutical, biotechnology, medical device, and CDMO manufacturing. The study included AI adoption rates, feature benchmarking, vendor AI maturity, estimated revenue contribution, workflow automation capabilities, and technology migration trends.
Helps stakeholders identify high-growth AI opportunities, benchmark competitors' digital capabilities, prioritize product investments, and develop AI-driven product roadmaps.
Digital Manufacturing & Smart Factory Adoption Analysis
Evaluated MES adoption across batch manufacturing, continuous manufacturing, biologics, cell & gene therapy, and medical device production, including integration with ERP, LIMS, QMS, SCADA, IIoT, and Digital Twin technologies. The analysis also assessed regional smart factory readiness and manufacturing digitalization maturity.
Provides insights into technology adoption trends, identifies high-investment manufacturing segments, and supports expansion strategies aligned with Industry 4.0 initiatives.
Life Sciences MES Market Opportunity & Competitive Landscape Assessment
Assessed market opportunities by deployment model (Cloud, Hybrid, On-premise), end user, manufacturing scale, and geography, along with vendor market share, pricing models, implementation ecosystem, regulatory readiness, whitespace opportunities, and strategic partnership analysis.
Supports market entry and expansion decisions by identifying underserved customer segments, evaluating competitive intensity, and uncovering long-term revenue opportunities across life sciences manufacturing.
Frequently Asked Questions About This Report
The global manufacturing execution system in life sciences market size was valued at USD 3.3 billion in 2025 and is estimated at USD 3.7 billion for 2026.
The global manufacturing execution system in life sciences market is expected to grow at a CAGR of 13.2% from 2026 to 2033, reaching USD 8.7 billion by 2033.
Based on end-user, the pharmaceutical and biotechnology companies segment led the market with the largest revenue share of 48.2% in 2025.
Some key players operating in the manufacturing execution system in life sciences market include Körber AG; Siemens AG; Rockwell Automation, Inc.; Emerson Electric Co.; AVEVA Group Limited; MasterControl Solutions Inc.; Critical Manufacturing S.A.; Honeywell International Inc.; SAP SE; ABB Ltd.; Cognizant Technology Solutions Corporation; Nagarro SE; iBASEt, Inc.; Dassault Systèmes SE
Key factors that are driving the market growth include increasing regulatory compliance, demand for real-time data and analytics, growing biopharmaceutical sector, technology advances, and globalization of the life sciences industry.
North America dominated the manufacturing execution system in life sciences market with a share of 31.6% in 2025. This is attributable to the increasing complexity of manufacturing processes along with the growing adoption of Industry 4.0 and digitalization.
Asia Pacific is the fastest-growing region over the forecast period.
Based on solution type, software segment dominated the market with the largest revenue share of 59.3% in 2025.
Based on deployment, the on-premise segment led the market with the largest revenue share of 50.0% in 2025.
About the Author(s)
Healthcare IT Research Team
Healthcare · Healthcare ITThis report was authored by the healthcare it research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the healthcare it segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
